Immix Biopharma

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Creative Medical Technology Holdings

PolarityTE Inc

Are these penny stocks on your watchlist right now? The post Best Penny Stocks to Buy Today?

Best Penny Stocks to Buy Today? 3 For Your Watchlist in January

The FDA has granted Rare Pediatric Disease (RPD) designation to newly listed Immix Biopharma Inc's (NASDAQ: IMMX) IMX-110 for rhabdomyosarcoma, a form of pediatric cancer. IMX-110 is currently being evaluated in Phase 1b/2a clinical trial.

Immix Shares Rally On FDA Rare Pediatric Disease Tag For Cancer Program In Children

Shares of Immix Biopharma Inc. IMMX, +9.20% rocketed 66.0% in premarket trading Monday, after the biopharmaceutical company said its IMX-110 was granted Rare Pediatric Disease (RPD) designation by the Food and Drug Administration for the threatment of pediatric cancer. The company said IMX-110 is current being evaluated in a Phase 1b/2a clinical trial.

Immix Biopharma's stock rockets after pediatric cancer treatment granted RPD by the FDA

LOS ANGELES, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for IMX-110 for the treatment of a life-threatening form of pediatric cancer in children, rhabdomyosarcoma. IMX-110, an investigational product, is currently being evaluated in a Phase 1b/2a clinical trial.

U.S. Food and Drug Administration Approves Immix Biopharma Rare Pediatric Disease Designation for IMX-110 as a Treatment for Life-Threatening Pediatric Cancer in Children

LOS ANGELES, CA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced the closing of its initial public offering of 4,200,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $21,000,000, before deducting underwriting discounts, commissions and offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 630,000 shares of common stock at the initial public offering price, less the underwriting discount, to cover over-allotments.

Immix Biopharma, Inc. Announces Closing of Initial Public Offering

LOS ANGELES, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, announced today the pricing of its initial public offering of 4,200,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $21,000,000 before deducting underwriting discounts, commissions and offering expenses. In addition, ImmixBio has granted the underwriters a 45-day option to purchase up to an additional 630,000 shares of common stock solely to cover over-allotments.

Immix Biopharma, Inc. Announces Pricing of Initial Public Offering

News for Immix Biopharma Stock (IMMX)